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ABSTRACT: Despite the vast availability of antibiotics, bacterial infections remain a leading cause of death worldwide. In an
effort to enhance the armamentarium against resistant bacterial strains, 1,2,3-triazole (5a−x) and sulfonate (7a−j) analogues of
natural bioactive precursors were designed and synthesized. Preliminary screening against two Gram-positive (Streptococcus
pneumoniae and Enterococcus faecalis) and four Gram-negative bacterial strains (Pseudomonas aeruginosa, Salmonella enterica,
Klebsiella pneumoniae, and Escherichia coli) was performed to assess the potency of these analogues as antibacterial agents.
Among all triazole analogues, 5e (derived from carvacrol) and 5u (derived from 2-hydroxy 1,4-naphthoquinone) bearing
carboxylic acid functionality emerged as potent antibacterial agents against S. pneumoniae (IC50: 62.53 and 39.33 μg/mL), E.
faecalis (IC50: 36.66 and 61.09 μg/mL), and E. coli (IC50: 15.28 and 22.57 μg/mL). Furthermore, 5e and 5u also demonstrated
moderate efficacy against multidrug-resistant E. coli strains and were therefore selected for further biological studies. Compound
5e in combination with ciprofloxacin displayed a synergistic effect on multidrug-resistant E. coli MRA11 and MRC17 strains,
whereas compound 5u was selective against E. coli MRA11 strain. Growth kinetic studies on S. pneumoniae and E. coli treated
with 5e and 5u showed an extended lag phase. 5e and 5u did not show significant cytotoxicity up to 100 μg/mL concentration
on human embryonic kidney (HEK293) cells. Transmission electron microscopic (TEM) analysis of bacterial cells (S.
pneumoniae and E. coli) exposed to 5e and 5u clearly showed morphological changes and damaged cell walls. Moreover, these
compounds also significantly inhibited biofilm formation in S. pneumoniae and E. coli strains, which was visualized by scanning
electron microscopic (SEM) analysis. Treatment of larvae of Galleria mellonella (an in vivo model for antimicrobial studies)
with 5e and 5u did not cause an alteration in the hemocyte density, thereby indicating lack of an immune response, and were
nontoxic up to a concentration of 2.5 mg/mL.
1. INTRODUCTION
The rising levels of multidrug-resistant (MDR) bacteria
coupled with the scarcity of upcoming antibiotics have
emerged as one of the most critical threats to public health
in the 21st century.1 Moreover, inappropriate use of available
antibiotics has further worsened the situation, making
previously treatable infections untreatable. As a result, efficacy
of the available antibiotics is diminishing at a faster rate.2 MDR
bacteria are responsible for infecting at least 2 million people
annually along with the fatalities of at least 90 000 people in
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the United States alone.3 Therefore, it has been recognized as
one of the top three threats by the World Health Organization
(WHO).4 A recent report by the Center for Disease Control
and Prevention (CDC) suggested that we are at the verge of
entering the “post-antibiotic era”.5 Thus, the development of
antimicrobials with novel modes of action to inhibit bacterial
infections is desperately required.
One of the most prominent features adopted by bacteria to
develop resistance toward antibiotics is the formation of
biofilms.6 Biofilms are highly hydrated organized structures,
usually attached to both biotic and abiotic surfaces, multi-
cellular communities of cells encased within the self-produced
protective extracellular matrix. The biofilm-producing bacteria
exhibit multifold resistance to conventional antibiotics and less
susceptibility to host immune defenses and the external
stresses.7 Biofilm-associated diseases such as cystic fibrosis
pneumonia, periodontitis, prostatitis, recurrent urinary tract
infection, and food-borne illnesses are posing serious threats to
human health.8 Moreover, clogged filtration membranes,
corroded pipes, or fouled immersed marine surfaces, which
act as a source for pathogens in water and food processing, are
other issues associated with biofilms.9
While a number of strategies are underway to develop
antimicrobials with the ability to inhibit biofilm formation,
modification of natural products has been proved to be a
promising approach. Various literature reports have cited the
role of natural products and their derivatives in the inhibition
of biofilm formation. The incorporation of a triazole moiety to
the naturally occurring compounds has resulted in potent
antimicrobial analogues. For example, flustramine C-inspired
pyrroloindoline-3-triazole amides,10 indole-triazole amide
conjugates,11 oroidin-triazole conjugates,12 2-aminoimidazole-
triazole conjugates,13 TAGE-triazole conjugates,14 pyrazolo-
[3,4-b]pyridine-triazole conjugates,15 triazole containing na-
amine A and isonaamine A mimics,16 and triazole derivatives of
geraniol and farnesol17 were found to inhibit the biofilm
formation of several Gram-negative and Gram-positive bacteria
(Figure 1).
Inspired by the significance of incorporation of 1,2,3-triazole
functionality in the natural scaffold and in continuation of
search for potent antimicrobial agents,18−21 we used hydroxyl-
containing natural bioactive precursors including carvacrol,
naphthoquinone, and 8-hydroxyquinoline for the modification.
We also incorporated sulfonate onto these natural alcohols for
comparison and screened all analogues against all tested
bacterial strains. Compared to their natural precursors,
compounds 5e and 5u showed significantly improved IC50
values against S. pneumoniae, E. faecalis, and E. coli. Growth
kinetic studies performed on S. pneumoniae and E. coli treated
with lead inhibitors (5e and 5u) showed their bacteriostatic
nature. Importantly, these compounds strongly inhibit the
formation of biofilm in the S. pneumoniae and E. coli strains and
showed moderate potency against the resistant E. coli isolates.
Furthermore, the selected compounds (5e and 5u) were also
subjected to in vitro (hemolysis and cytotoxicity assays) as well
as in vivo toxicity assays on G. mellonella and found to be
nontoxic. The study revealed that 5e and 5u provide a suitable
core to be exploited for further structure−activity relationship
(SAR) studies to develop potent antibacterial agents.
2. RESULTS AND DISCUSSION
2.1. Chemistry. The 1,2,3-triazole analogues (5a−x) of
natural precursors were synthesized using the general synthesis
approach, as shown in Scheme 1. Commercially available
Figure 1. Natural product-based 1,2,3-triazole analogues as anti-biofilm agents.
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carvacrol (1a), 8-hydroxyquinoline (1b), and 2-hydroxy-1,4-
naphthoquinone (1c) were propargylated in the presence of
propargyl bromide and potassium carbonate to yield
corresponding alkyne (2a−c). In another set of reaction,
variously substituted aniline bearing electron-withdrawing/
electron-donating groups (3a−h) were converted into their
corresponding azides (4a−h) via diazotization using sodium
nitrite and hydrochloric acid followed by sodium azide
treatment. Finally, azide (4a−h) and alkyne (2a−c) underwent
Cu(I)-catalyzed [3 + 2] cycloaddition reaction in the presence
of catalytic amount of CuSO4·5H2O and sodium ascorbate in
tetrahydrofuran (THF)/H2O (1:2) mixture to yield the title
compounds (5a−x) in quantitative yields (Scheme 1).
For the synthesis of sulfonic esters, natural precursors (1a−
b) were treated with aryl/heteroaryl/aliphatic sulfonyl
chlorides (6a−e) in the presence of triethylamine base to
yield sulfonate derivatives (7a−j) in quantitative yield
(Scheme 2). All intermediates and title compounds (5a−x)
and (7a−j) were well characterized using multi spectroscopic
techniques, and purity was established by liquid chromatog-
raphy (LC)−mass spectrometry (MS). Single crystal structures
of 1,2,3-triazole derivatives (5c and 5f) and sulfonic ester
derivatives (7g and 7h) were also recorded to further confirm
the proposed structures.
2.2. X-ray Crystallographic Analysis. Single X-ray crystal
structure analysis of 1,2,3-triazole derivatives (5c and 5f) and
sulfonic ester derivatives (7g and 7h) was done to support
structural analysis data. The crystal data and structure
refinement details are presented in Table 1. A colorless crystal
of compound 5c (C19H20ClN3O), with approximate dimen-
sions of 0.18 × 0.10 × 0.03 mm3, was used for X-ray
crystallographic analysis. The compound crystallized in a
triclinic crystal system with the space group P1̅ (Figure 2A).
The unit cell contains two molecules with similar conforma-
tions, through which strong C−H···N hydrogen bonds (C1A−
H1A···N2B 2.611 Å; C1B−H1B···N2A 2.430 Å; C22A−
H22A···N3B 2.361 Å; C22B−H22B···N3A 2.488 Å) generate
linear chains along the a-axis with alternative orientation of A
and B molecules (Figure 2B). Moreover, the crystal packing of
5c presents the formation of additional C−H···π interaction
between the molecules (C3A−H3A···C24A 2.734 Å) and C−
H···O interactions between the molecules (C12B−H12E···
O1B 2.688 Å). These interactions led to the formation of
dimeric units (see Figure S1 in the Supporting Information).
Figure 2C represents the XP diagram of the compound 5f
with 50% probability level of thermal ellipsoids. The structure
of compound 5f (C20H23N3O), a colorless platelike specimen,
with approximate dimensions of 0.072 × 0.233 × 0.255 mm3,
was elucidated by X-ray crystallographic analysis. The crystal
structure analysis revealed that it crystallizes in a monoclinic
crystal system with the space group P21/c. In the packing
diagram of 5f, linear chains along the b-axis containing a
double layer of alternating molecules were observed (Figure
2D). These chains are formed via C−H···N hydrogen bonds
and C−H···π and π···π interactions. The shortest distance
between the triazole derivative units is 3.392 Å and represents
the centroid distance Cg1···Cg1. Two types of C−H···N
hydrogen bonds were found, one between two neighbored
triazole units and the second type between one triazole ring
and the phenyl substituent at N1 atom (C1−H1···N2 2.381 Å;
C22−H22···N3 2.641 Å). In addition, C−H···π interaction
involving two phenoxy substituents (C13−H13···Cg2 2.683 Å)
is contributing to the stability of this packing diagram. The
resulted double layer chains are along the c-axis connected via
π···π interactions between the triazole ring and the phenyl
substituent (Cg3···Cg4 3.408 Å) (see Figure S2 in the
Supporting Information).
X-ray crystallographic analysis of compound 7g
(C15H10N2O5S), a colorless needlelike specimen, of approx-
imate dimensions 0.092 × 0.169 × 0.322 mm3 revealed that it
crystallizes in a monoclinic crystal system with the space group
P21/c. The XP diagram of compound 7g with ellipsoids drawn
at a 50% probability level along with the atomic numbering
scheme is shown in Figure 3A. In the packing diagram, a
complex three-dimensional (3D) network involving intermo-
lecular C−H···O and π···π interactions was found. The partial
Scheme 1. Synthesis of 1,2,3-Triazole Derivatives of Natural Precursors
Scheme 2. Synthesis of Sulfonic Esters of Natural
Precursors
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overlapping mode between the nitrobenzene substituent and
the quinoline unit (Cg1···Cg2 3.288 Å) combined with C−H···
O hydrogen bonds involving the sulfonate unit leads to the
formation of wave chains along the b-axis (Figure 3B).
Additional C−H···O hydrogen bonds of the nitro and
sulfonate groups complete the 3D network (see Table S17 in
the Supporting Information).
X-ray crystallographic analysis was used to unambiguously
confirm the structure of compound 7h (C16H13NO3S), a
colorless platelike specimen, with approximate dimensions of
0.020 × 0.100 × 0.160 mm3. Crystal structure analysis of
compound 7h revealed that it crystallizes in a triclinic crystal
system with the space group P1̅. The XP diagram of compound
7h with ellipsoids drawn at a 50% probability level along with
atomic numbering scheme is shown in Figure 3C. For
compound 7h, a 3D network involving C−H···O, C−H···N,
C−H···π, and π···π interactions was observed. In contrast to
the packing diagram of 7h, a lower overlapping mode between
quinoline and p-tolyl groups was observed. The strongest
interactions (C−H···O hydrogen bonds) were found between
sulfonate and quinoline groups (C8−H8···O1 2.466 Å) and are
leading to the formation of dimeric units. These dimers are
connected along ab-diagonal through weak π···π interactions to
linear chains (Figure 3D). Additional interactions (C−H···O,
C−H···π, and C−H···N) are stabilizing the structure of this
compound (see Table S21 in the Supporting Information).
2.3. In Vitro Antibacterial Activity. All natural precursors
and their triazole/sulfonate analogues were primarily screened
for antibacterial activity against Gram-positive (S. pneumoniae
and E. faecalis) and Gram-negative (P. aeruginosa, S. enterica, K.
pneumoniae, and E. coli) sensitive bacterial strains. Cipro-
floxacin (CIP) was used as a reference drug, and the results are
presented in terms of IC50 values in Table 2. The results
showed that compounds exhibited moderate to potent
antibacterial activity against both Gram-positive and Gram-
negative bacteria. Moreover, as compared to natural
precursors, compounds 5e and 5u with p-carboxylic acid
substitution emerged as potent inhibitors of E. coli with IC50
values of 15.28 and 22.57 μg/mL, respectively. Moreover,
these compounds also inhibited the growth of S. pneumoniae
(62.53 and 39.33 μg/mL, respectively) as well as E. faecalis
with IC50 values of 36.66 and 61.09 μg/mL, respectively. It was
observed that the corresponding analogue of quinoline, 5m,
exhibited moderate inhibitory effect on the same bacterial
strains (S. pneumoniae, E. faecalis, and E. coli). The analogues of
carvacrol (5a) and quinoline (5i) with unsubstituted phenyl
substituent clearly lost their potential against all bacterial
strains, whereas the corresponding analogue of naphthoqui-
none (5q) displayed IC50 values of 96.99, 101.23, and 99.53
μg/mL against S. pneumoniae, E. faecalis, and E. coli,
respectively. None of the halogen-substituted (p-fluoro and
p-chloro substitution) compounds exhibited potency against
any of the bacterial strains except compound 5r with p-fluoro
substitution, which showed a modest effect on S. pneumoniae
and E. coli with IC50 values of 133.86 and 164.78 μg/mL,
respectively. Except the moderate effect of compound 5d on K.
pneumoniae (IC50 = 121.83 μg/mL), none of the p-nitro-
substituted analogues exhibited potency against any of the
strains tested. The analogues bearing electron-donating
substituents such as p-methyl and p-methoxy exhibited better
inhibition of all bacterial strains in comparison to halogen-
substituted (p-fluoro and p-chloro substitution) analogues,
where the activity was considerably lost against all strains.
Among all p-sulfonamide-substituted analogues, 5x moderately
inhibited the growth of S. pneumoniae and E. coli strains with
IC50 values of 85.23 and 103.54 μg/mL, respectively, whereas
Table 1. Crystal Data and Structure Refinement Details for 5c, 5f, 7g, and 7h
identification code 5c 5f 7g 7h
formula C19H20ClN3O C20H23N3O C15H10N2O5S C16H13NO3S
MW (g/mol) 341.83 321.41 330.31 299.33
dcalcd (g cm
−3) 1.268 1.219 1.589 1.455
crystal size (mm) 0.18 × 0.10 × 0.03 0.072 × 0.233 × 0.255 0.092 × 0.169 × 0.322 0.020 × 0.100 × 0.160
T/K 223(2) 104(2) 104(2) 100(2)
λ (Å) 0.71073 0.71073 0.71073 1.54178
F(000) 720 688 680 312
crystal system triclinic monoclinic monoclinic triclinic
space group P1̅ P21/c P21/c P1̅
a (Å) 11.0378(3) 20.1641(12) 10.3165(4) 8.9865(3)
b (Å) 11.8494(4) 5.4625(3) 11.1535(4) 9.2432(3)
c (Å) 13.7117(5) 16.6110(10) 12.6841(5) 9.3299(3)
α (deg) 92.880(2) 90 90 66.983(2)
β (deg) 90.142(2) 106.857(2) 108.871(2) 79.673(2)
γ (deg) 91.245(2) 90 90 73.972(2)
V (Å3) 1790.67(10) 1751.02(18) 1381.05(9) 683.32(4)
Z 4 4 4 2
θ range (deg) 4.11−25.00 2.47−26.37 2.49−27.51 5.14−68.09
collected reflections 8979 33 271 21 467 9610
unique reflections; Rint 6136 [Rint = 0.0381] 3567 [Rint = 0.0611] 3169 [Rint = 0.0568] 2382 [Rint = 0.0348]
μ/mm−1 0.223 0.077 0.264 2.196
R(Fo), [I > 2σ(I)] 0.0787 0.0672 0.0354 0.0322
Rw(Fo
2) (all data) 0.1177 0.0821 0.0486 0.0360
GoF (F2) 1.101 1.167 1.062 1.083
Δρ [e Å−3] 0.298/−0.249 0.269/−0.295 0.337/−0.477 0.316/−0.363
CCDC number 1516149 1516150 1516148 1516147
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it exhibited potent effect on E. faecalis with an IC50 value of
39.23 μg/mL. Among all sulfonic ester analogues (7a−j), the
compound derived from carvacrol (7a) with an unsubstituted
phenyl ring displayed a moderate activity against E. coli and K.
pneumoniae with IC50 values of 112.94 and 117.09 μg/mL,
respectively. Compound 7d with n-butyl tail exhibited an IC50
value of 95.54 μg/mL against K. pneumoniae. Compounds 7d
and 7e with a thiophenyl ring displayed moderate potency
against P. aeruginosa with IC50 values of 118.45 and 119.04 μg/
mL, respectively. None of the sulfonic esters derived from
quinoline exhibited a significant effect on any of the bacterial
strains. The in vitro antibacterial evaluation results showed the
importance of incorporation of a triazole scaffold over sulfonic
esters.
On the basis of the results obtained on sensitive bacterial
strains, compounds 5e and 5u were selected for further
screening on eight multidrug-resistant E. coli strains. It was
observed that at 1024 μg/mL concentration [minimum
inhibitory concentration (MIC)], compounds 5e exhibited
more than 95% inhibition of E. coli MRA11, MRC24,
MRAE26, MRAE32, and MROB11 strains, whereas at the
same concentration, it caused 79, 86, and 86% inhibition of E.
coli MRC17, MRAE33, and MRAE44 strains, respectively.
Compound 5u at the MIC value (1024 μg/mL) caused nearly
100% inhibition of the growth of MRC17, MRC24, MRAE26,
MRAE32, MRAE33, and MROB11 strains, whereas it caused
only 70% inhibition of MRAE44 growth, showing moderate
efficacy on this strain. 5u was also effective on MRA11 strain,
causing more than 90% inhibition of growth, indicating
moderate efficacy of these compounds in comparison to CIP,
which showed almost 100% inhibition at a concentration lower
than those of the compounds (Figure 4). These compounds
were further evaluated for their in vitro synergistic effects in
combination with CIP against E. coli MRA11, MRC17, and
MRAE33 strains. The results indicated that antibacterial
activity of 5e against all three strains was significantly enhanced
when used in combination with CIP. Compound 5u in
combination with CIP exhibited a significant improvement in
antibacterial activity against E. coli MRAE33, whereas it
exhibited a moderate activity against E. coli MRA11. The
fractional inhibitory concentration index (FICI) values of
compound 5e were 0.03 against E. coli MRA11 and MRC17
strains, indicating high synergistic effect, whereas compound
5u exhibited partial synergy against E. coli MRA11 with an
FICI value of 0.62. None of the compound exhibited
synergistic effect in combination with CIP against E. coli
MRAE33 (Tables 3 and 4). These results prompted us to
explore the effect of these inhibitors (5e and 5u) on the
growth kinetics of S. pneumoniae and E. coli. The kinetic studies
showed that both compounds exhibited inhibitory effects on
the growth pattern of S. pneumoniae and E. coli strains.
Compound 5e was found to be more potent as it effectively
inhibited the growth of S. pneumoniae even at a sub-MIC
concentration (62.5 μg/mL). Furthermore, no significant
growth of E. coli was observed at MIC and 2MIC
concentrations up to 22 h of incubation, whereas at a sub-
Figure 2. (A) XP diagram of compound 5c with atomic labeling scheme (50% probability level of thermal ellipsoids); (B) excerpt of the packing
diagram of 5c representing the chain formation along the a-axis via CH···N interactions; (C) XP diagram of compound 5f with atomic labeling
scheme (50% probability level of thermal ellipsoids); and (D) linear double-layer chain formation through CH···N interactions along the b-axis in
5f.
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MIC concentration, a suppressed growth was observed with a
lag phase of approximately 6 h. Compound 5u was found to be
less effective as growth in S. pneumoniae could be observed in 8
and 9 h at sub-MIC and MIC concentrations, respectively,
whereas in the case of E. coli, growth was observed at 6 and 9 h
at sub-MIC and MIC concentrations of 5u. An increase in
turbidity representing bacterial growth post 22 h in all test
cultures indicated the bacteriostatic nature of 5e and 5u
(Figure 5).
2.4. TEM Analysis of S. pneumoniae and E. coli Cells
Treated with 5e and 5u. TEM analysis was performed to
check the effect of 5e and 5u on the morphology of S.
pneumoniae and E. coli cells. The cell culture of E. coli treated
with MIC concn of 5e and 5u and untreated cells (control)
were used for TEM analysis. It was observed that the treated
cells showed moderate to severe cellular deformities, whereas
untreated cells were normal in shape with an intact cell wall.
The treatment of bacterial cells with 5e and 5u significantly
damaged the cell wall, resulting in the loss of integrity and
cytosolic oozing. The degraded cell wall of bacteria observed in
the TEM micrographs proposes the bactericidal activity of test
compounds. Their antibacterial mode of action needs to be
further characterized (Figure 6).
2.5. Effect of 5e and 5u on the Biofilm Formation.
2.5.1. Assessment of Anti-Biofilm Activity by Tetrazolium
Salt (XTT) Reduction Assay. The effect of lead compounds (5e
and 5u) on biofilm formation was determined using E. coli and
S. pneumoniae strains. The compounds exhibited significant
inhibition of biofilm formation in both the strains. Compounds
5e and 5u inhibited the biofilm formation in E. coli by 95.23
and 92.26% at a concentration of 125 μg/mL (2MIC) of 5e
and 250 μg/mL (2MIC) of 5u, respectively. Similarly, in the
case of S. pneumoniae, 92.26 and 100% inhibition was observed
at a concentration of 250 μg/mL (2MIC) of 5e and 5u,
respectively. From the results, it was concluded that both
compounds could be further customized to develop as potent
anti-biofilm agents (Figure 7).
2.5.2. Assessment of Anti-Biofilm Activity by Crystal Violet
Assay. Anti-biofilm activity of the lead compounds (5e and
5u) on E. coli and S. pneumoniae strains was further determined
by crystal-violet assay. Compound 5e inhibited the biofilm
formation in E. coli by 94.32% at 125 μg/mL (2MIC)
concentration and in S. pneumoniae by 93.36% at a
Figure 3. (A) XP diagram of compound 7g with atomic labeling scheme (50% probability level of thermal ellipsoids); (B) wave chain along the b-
axis formed via π···π and CH···O interactions in the packing diagram of 7g; (C) XP diagram of compound 7h with atomic labeling scheme (50%
probability level of thermal ellipsoids); and (D) linear chain of dimeric units along ab-diagonal formed via CH···O and π···π interactions in the
packing diagram of 7h.
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Table 2. In Vitro Antibacterial Activity (IC50) of 1,2,3-Triazole and Sulfonic Esters of Natural Precursors (μg/mL)
a
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concentration of 250 μg/mL (2MIC). Similarly, compound 5u
inhibited the biofilm formation by 77.26 and 98.28% in E. coli
and in S. pneumoniae, respectively, at a concentration of 250
μg/mL (2MIC) (Figure 7). To assess the viability of bacterial
cells post treatment, colony forming unit (CFU) count was
also performed (Table 5). The viability data showed that
compounds 5e and 5u were able to reduce the colony
formation of bacterial cells when compared with untreated
counterparts. Analysis of biomass formation in control and
treated samples demonstrated higher biomass formation in
control samples. The OD590 values presenting the biofilm
formation via viable cells revealed maximum biomass in the
control sample followed by samples treated with test
compounds 5e and 5u followed by CIP-treated cells, thus
showing a maximum antimicrobial activity (Figure 8).
2.5.3. Assessment of Biofilm Inhibition by SEM Analysis.
SEM analysis was also carried out to validate the effect of lead
compounds 5e and 5u on biofilm formation in E. coli strain.
On exposure to the 2MIC concentration of 5e and 5u,
significant inhibition of biofilm formation was observed in the
treated cells. In untreated samples, the cells appeared in
clusters with a polysaccharide matrix, which showed the
formation of a biofilm, whereas cells treated with 2MIC
concentration of 5e showed scattered single cells with
significant cell damage. Compound 5u, although significantly
effective in inhibiting biofilm formation, was less potent than
5e as the cell integrity was lost to lesser extent in the latter case
(Figure 9).
2.6. Toxicity Evaluation of Lead Compounds by in
Vitro (MTT and Hemolytic Assay) and in Vivo (on G.
mellonella Larvae) Studies. 2.6.1. Toxicity Studies by MTT
and Hemolytic Assays. The cytotoxicity of the lead inhibitors
(5e and 5u) was evaluated by MTT assay on HEK293 cells
(Figure 10A). The results showed that both the compounds
retained more than 75% cell viability at 50 μg/mL
concentration but exhibited moderate toxicity at a concen-
tration of 200 μg/mL (more than 50% cell viability). On
increasing the concentration to 400 μg/mL, cell viability
further decreased, which indicated that the compounds possess
some toxicity at higher concentrations. At the IC50
concentration, these compounds could be considered nontoxic
and thus can be further investigated for in vivo evaluation. To
exclude any possible toxicity on human red blood cells
(hRBCs), hemolytic assay was also performed with 5e and 5u.
At 200 μg/mL concentration, compounds 5e and 5u caused
only 9% cell lysis in comparison to 0.8% cell lysis caused by
CIP at the same concentration. More interestingly, compounds
5e and 5u were found to exhibit insignificant toxicity up to 600
μg/mL with only 22 and 12% cell lysis, respectively (Figure
10B).
Table 2. continued
aThe value obtained in at least three separate assays done in triplicate.
Figure 4. In vitro antibacterial activity of 5e, 5u, and CIP (μg/mL)
against multidrug-resistant E. coli strains: MRA11, MRC17, MRC24,
MRAE26, MRAE32, MRAE33, MRAE44, and MROB11. The
numbers written above the respective columns correspond to the
MIC concentrations of 5e, 5u, and CIP.
Table 3. In Vitro Synergistic Effect of 5e
MIC alone
(μg/mL)
MIC in
combina-
tion
(μg/mL)
E. coli strain 5e CIP 5e CIP FICIa mode of interaction
MRA11 1024 128 16 2 0.03 synergistic
MRC17 1024 128 16 2 0.03 synergistic
MRAE33 1024 2 16 2 1.02 indifferent
aSynergy and antagonism were defined by FICI ≤ 0.5 and >4,
respectively. Partially synergistic was denoted by 0.5 > FICI < 1, and
indifferent was defined by 1 < FICI ≤ 4.
Table 4. In Vitro Synergistic Antibacterial Activity of 5u
MIC alone
(μg/mL)
MIC in
combination
(μg/mL)
E. coli strain 5u CIP 5u CIP FICIa mode of interaction
MRA11 1024 128 512 16 0.62 partially synergistic
MRC17 1024 128 1024 64 1.50 indifferent
MRAE33 1024 2 16 2 1.02 indifferent
aSynergy and antagonism were defined by FICI ≤ 0.5 and >4,
respectively. Partially synergistic was denoted by 0.5 > FICI < 1, and
indifferent was defined by 1 < FICI ≤ 4.
ACS Omega Article
DOI: 10.1021/acsomega.8b00582
ACS Omega 2018, 3, 6912−6930
6919
Figure 5. Growth kinetic studies under different concentrations of test compounds. (A,B) treated with 5e and (C,D) treated with 5u.
Figure 6. Representative transmission electron micrographs of (A) E. coli and (B) S. pneumoniae cells exposed to 5e (62.5 and 125 μg/mL
concentrations, respectively) and 5u (125 μg/mL concentration) at their respective MICs.
Figure 7. Percentage of biofilm inhibition in E. coli and S. pneumoniae on treatment with 5e and 5u using (A) XTT assay and (B) crystal violet
assay. The numbers (125 and 250) written above the respective columns correspond to the 2MIC concentrations of 5e and 5u, respectively.
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2.7. In Vivo Toxicity Evaluation of 5e and 5u on G.
mellonella Larvae. Because immune response of insects
exhibits remarkable similarities to the innate immune response
of mammals, insects have been used as models for the
evaluation of toxicity of antimicrobial drugs. It has been
reported previously that G. mellonella has been utilized to
assess the toxicity of novel antimicrobial drugs and the results
showed a strong correlation with those obtained using
mammals.22 An in vivo study on the larvae of G. mellonella
showed that viability of the larvae was not affected up to the
concentration of 2.5 mg/mL of test compounds (5e and 5u),
indicating their nontoxic behavior towards the larvae (Figure
11A−C). Moreover, at the same concentration, hemocyte
density of the larvae was not significantly affected, which
indicated lack of an immune response (Figure 11D).
2.8. Absorption, Distribution, Metabolism, and
Excretion (ADME) Profiling. The computational prediction
of important physicochemical descriptors related to absorp-
tion, distribution, metabolism, and excretion properties
represents a cost-effective strategy to filter out molecules at
early stages of drug-discovery process.23 Here, we did in silico
physicochemical prediction for all analogues (5a−x and 7a−j)
using QikProp version 3.2, Schrödinger software.24 Partic-
ularly, we predicted total polar surface area, the number of
rotatable bonds (NRB), aqueous solubility (QP log S), binding
to human serum albumin (QP log Khsa), brain/blood partition
coefficient (QP log BB), Caco-2 and MDCK permeability, and
estimation of % human oral absorption, which indicated the
druglike characteristics of these compounds. In addition,
Lipinski’s parameters for drug-likeliness were also calculated,
which states that any orally active drugs should not violate
more than one of its parameters.25 These compounds follow
Lipinski’s rule of 5 and possessed moderate to good % human
oral absorption. Therefore, these compounds have the
potential to be carried forward for SAR and pharmacological
investigations. All results of in silico physicochemical
prediction are summarized in Table S1 (Supporting
Information).
3. CONCLUSIONS
In summary, a novel series of 1,2,3-triazole/sulfonate
analogues derived from natural bioactive alcohols were
synthesized and evaluated for their potential as antibacterial
agents against a panel of Gram-positive and Gram-negative
bacterial strains. Most of the compounds displayed good to
moderate antibacterial activity across the panel. Compounds
5e and 5u emerged as potent antibacterial agents against
sensitive S. pneumoniae, E. faecalis, and E. coli strains as well as
moderately effective against MDR E. coli strains. Compound 5e
in combination with CIP showed a synergistic effect on MDR
E. coli MRA11 and MRC17 strains, whereas compound 5u was
selective against E. coli MRA11. Further, growth kinetic studies
confirmed the bacteriostatic nature of the test compounds.
TEM analysis showed that 5e and 5u caused significant cell
wall damage and membrane disruption of bacterial cells (S.
pneumoniae and E. coli), leading to cell death. Moreover, these
compounds were also found to be potent anti-biofilm agents
on S. pneumoniae and E. coli strains and exhibited non-
cytotoxicity on the HEK293 cell line up to a concentration of
100 μg/mL. Besides, these compounds did not cause an
alteration in the hemocyte density, indicating the lack of an
immune response, and were nontoxic on the larvae of G.
mellonella up to the concn of 2.5 mg/mL. Our study firmly
supports further structural optimization of these compounds
(5e and 5u) for the development of potent and safer
antibacterial agents.
4. EXPERIMENTAL SECTION
4.1. Chemistry. All chemicals and solvents (analytical
grade) were purchased from Sigma-Aldrich, USA. Thin-layer
chromatographic analysis was carried out on precoated Merck
silica gel 60 F254 TLC aluminum sheets, and spots were
visualized under UV light at 254 nm and I2 vapor staining. IR
spectra were recorded on an Agilent Cary 630 Fourier
transform infrared spectrometer, and only major peaks are
Table 5. CFUs of E. coli and S. pneumoniae Observed in
Treated and Untreated Bacterial Cells
E. coli S. pneumoniae
control 1.67 × 105 1.1 × 104
CIP 2.0 × 104 5.0 × 103
5e 2.5 × 104 7.8 × 103
5u 2.7 × 104 6.0 × 103
Figure 8. Biomass determination in E. coli and S. pneumoniae at
OD590.
Figure 9. SEM images showing biofilm inhibition in E. coli.
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reported in cm−1. 1H and 13C NMR spectra were obtained in
CDCl3/DMSO-d6 as a solvent with tetramethylsilane as an
internal standard on a Bruker SpectroSpin DPX-300
spectrometer at 300 and 75 MHz, respectively. Splitting
patterns are designated as follows: s (singlet), d (doublet), t
(triplet), m (multiplet), sep (septet), or br s (broad). 1H NMR
chemical shift (δ) values are reported in parts per million
(ppm) relative to residual solvent (CDCl3, δ 7.26; DMSO-d6, δ
2.54), 13C NMR chemical shifts (δ) are reported in ppm
relative to CDCl3 (δ 77.16; DMSO-d6, δ 39.5), and coupling
constants (J) are expressed in hertz (Hz). Mass spectra were
recorded on an Agilent Quadrupole-6150 LC−MS spectrom-
eter. Melting points were measured on a digital Buchi melting
point apparatus (M-560) and are uncorrected. Purity was
determined by an Agilent RRLC MS 6320 ion trap
spectrometer using an XBridge C18 1.7 μm column (50 mm
× 2.1 mm). Mobile phase channel A consisted of 5 mM
ammonium acetate in water. Mobile phase B consisted of
acetonitrile with a flow rate = 0.8 mL/min; detection was done
by UV@214 nm, and all final compounds were confirmed to
have ≥95% purity. Purification of the compounds was carried
out by silica gel column chromatography (230−400 mesh size)
with the indicated eluent.
4.2. General Procedure for the Synthesis of Alkynes
(2a−c). A solution of natural precursors (1a−c) (1.0 mmol) in
anhyd dimethylformamide (10 mL) and potassium carbonate
(2.0 mmol) was allowed to stir for 15 min at room
temperature. To this solution, propargyl bromide (1.2 mmol)
was added dropwise, and the reaction mixture was stirred
overnight under argon. After completion of the reaction, the
reaction mixture was quenched by the addition of water and
extracted with ethyl acetate. The combined organic layers were
washed with brine, dried over anhyd sodium sulfate, and
concentrated under vacuo. The crude product was then
Figure 10. (A) Cell viability assay on HEK293 cell line and (B) hemolytic assay for compounds 5e, 5u, and CIP on hRBCs.
Figure 11. Percentage viability of G. mellonella larvae in the presence of (A) 5e; (B) 5u; (C) dimethyl sulfoxide (DMSO); (D) hemocyte densities
of larvae.
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purified by column chromatography using ethyl acetate/hexane
(3:7) to yield the pure alkyne.20
4.2.1. 4-Isopropyl-1-methyl-2-(prop-2-ynyloxy)benzene
(2a). Colorless oil, yield: 87%, Rf = 0.75 (ethyl acetate/hexane
= 30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 7.05 (d, J =
7.5 Hz, 1H), 6.81−6.76 (m, 2H), 4.69 (s, 2H), 2.87 (sep, J =
6.9 Hz, 1H), 2.48 (t, 1H), 2.20 (s, 3H), 1.24 (d, J = 6.9 Hz,
6H); 13C NMR (75 MHz, CDCl3) (δ, ppm): 155.83, 147.85,
130.74, 124.61, 119.17, 110.45, 79.22, 75.17, 56.07, 34.13,
24.12, 15.87; ESI-MS (m/z): 189.2 [M + H]+.
4.2.2. 8-(Prop-2-ynyloxy)quinoline (2b). Yellow oil, yield:
89%, Rf = 0.48 (ethyl acetate/hexane = 30:70);
1H NMR (300
MHz, CDCl3) (δ, ppm): 8.95−8.94 (m, 1H), 8.15 (dd, J = 8.1,
1.2 Hz, 1H), 8.01 (s, 1H), 7.52−7.42 (m, 2H), 7.29−7.26 (m,
1H), 5.04 (s, 2H), 2.54 (s, 1H); 13C NMR (75 MHz, CDCl3)
(δ, ppm): 162.46, 153.07, 149.38, 135.88, 129.46, 126.39,
121.66, 120.99, 110.05, 78.29, 76.05, 56.51; ESI-MS (m/z):
184.1 [M + H]+.
4.2.3. 2-(Prop-2-ynyloxy)naphthalene-1,4-dione (2c). Red-
dish-orange solid, yield: 58%, mp 154−156 °C, Rf = 0.71 (ethyl
acetate/hexane = 30:70); 1H NMR (300 MHz, CDCl3) (δ,
ppm): 8.11−8.08 (m, 2H), 7.79−7.70 (m, 2H), 6.36 (s, 1H),
4.81 (s, 2H), 2.66 (s, 1H); 13C NMR (75 MHz, CDCl3) (δ,
ppm): 184.66, 179.77, 158.06, 134.34, 133.44, 131.89, 131.07,
126.72, 126.21, 111.65, 78.17, 75.47, 56.73; ESI-MS (m/z):
145.1.
4.3. General Procedure for the Synthesis of Azides
(4a−h). To a solution of substituted aniline (3.22 mmol) in
ethyl acetate (6.44 mL) kept at 0 °C was added conc
hydrochloric acid (1.29 mL) followed by dropwise addition of
a solution of NaNO2 (3.87 mmol) in water (4.03 mL) over a
period of 10 min with constant stirring. After stirring the
reaction mixture for 1 h at 0 °C, a solution of NaN3 (3.87
mmol) in water (4.03 mL) was added to this mixture and
allowed to stir at room temperature for 3 h. After completion
of the reaction, the mixture was poured into water, extracted
with ethyl acetate, dried over anhyd sodium sulfate, and
concentrated under vacuo to give azide, which was used further
without purification.26
4.4. General Procedure for the Synthesis of 1,2,3-
Triazole of Natural Precursors (5a−x). To a solution of
substituted aryl azide (1.06 mmol) and alkyne (1.06 mmol) in
a mixed solvent system, THF/H2O (1:2, 9 mL), were added
sodium ascorbate (0.55 mmol) and CuSO4·5H2O (0.18
mmol). The reaction mixture was stirred overnight at room
temperature. After completion of the reaction, the solid
obtained was filtered and washed with water. The crude
product was purified by silica gel chromatography using a
solution of ethyl acetate/hexane (1:9), ethyl acetate/hexane
(3:7), and ethyl acetate/hexane (5:5) to yield pure triazole
derivatives of carvacrol, 2-hydroxynaphthoquinone, and 8-
hydroxyquinoline, respectively.26
4.4.1. 4-((5-Isopropyl-2-methylphenoxy)methyl)-1-phe-
nyl-1H-1,2,3-triazole (5a). Creamish solid, yield: 90%, mp
106−108 °C, Rf = 0.60 (ethyl acetate/hexane = 30:70); 1H
NMR (300 MHz, CDCl3) (δ, ppm): 8.03 (s, 1H), 7.74 (d, J =
7.8 Hz, 2H), 7.55−7.42 (m, 3H), 7.08 (d, J = 7.5 Hz, 1H),
6.88 (s, 1H), 6.78 (d, J = 7.2 Hz, 1H), 5.32 (s, 2H), 2.87 (sep,
J = 6.9 Hz, 1H), 2.23 (s, 3H), 1.25 (d, J = 6.9 Hz, 6H); 13C
NMR (75 MHz, CDCl3) (δ, ppm): 156.32, 148.12, 145.68,
137.07, 130.66, 129.78, 128.84, 124.27, 120.64, 118.86, 110.13,
62.39, 34.11, 24.13, 15.94; ESI-MS (m/z): 308.2 [M + H]+,
330.7 [M + Na]+.
4 . 4 . 2 . 1 - ( 4 - F l uo ropheny l ) - 4 - ( ( 5 - i sop ropy l - 2 -
methylphenoxy)methyl)-1H-1,2,3-triazole (5b). Creamish
solid, yield: 88%, mp 110−113 °C, Rf = 0.63 (ethyl acetate/
hexane = 30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 7.98
(s, 1H), 7.74−7.69 (m, 2H), 7.26−7.18 (m, 2H), 7.08 (d, J =
7.5 Hz, 1H), 6.87 (s, 1H), 6.79 (d, J = 7.5 Hz, 1H), 5.31 (s,
2H), 2.87 (sep, J = 6.9 Hz, 1H), 2.22 (s, 3H), 1.25 (d, J = 6.9
Hz, 6H); 13C NMR (75 MHz, CDCl3) (δ, ppm): 164.14,
160.84, 156.28, 148.14, 145.84, 133.33, 130.67, 124.25, 122.68,
122.57, 120.74, 118.90, 116.90, 116.59, 110.11, 62.34, 34.09,
24.11, 15.91; ESI-MS (m/z): 326.2 [M + H]+.
4 .4 . 3 . 1 - ( 4 -Ch lo ropheny l ) - 4 - ( ( 5 - i sop ropy l - 2 -
methylphenoxy)methyl)-1H-1,2,3-triazole (5c). Creamish
solid, yield: 91%, mp 116−118 °C, Rf = 0.57 (ethyl acetate/
hexane = 30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 8.00
(s, 1H), 7.70 (d, J = 8.1 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H),
7.08 (d, J = 7.2 Hz, 1H), 6.87 (s, 1H), 6.79 (d, J = 7.2 Hz,
1H), 5.32 (s, 2H), 2.88 (sep, J = 7.2 Hz, 1H), 2.22 (s, 3H),
1.24 (d, J = 6.6 Hz, 6H); 13C NMR (75 MHz, CDCl3) (δ,
ppm): 156.26, 148.14, 145.97, 135.54, 134.64, 130.68, 129.96,
124.25, 121.76, 120.45, 118.94, 110.13, 62.32, 34.09, 24.11,
15.90; ESI-MS (m/z): 342.1 [M + H]+.
4.4.4. 4-((5-Isopropyl-2-methylphenoxy)methyl)-1-(4-ni-
trophenyl)-1H-1,2,3-triazole (5d). Light yellow solid, yield:
87%, mp 114−116 °C, Rf = 0.70 (ethyl acetate/hexane =
30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 8.42 (d, J =
5.1 Hz, 2H), 8.15 (s, 1H), 7.99 (d, J = 5.4 Hz, 2H), 7.09 (d, J
= 7.5 Hz, 1H), 6.86 (s, 1H), 6.80 (d, J = 7.8 Hz, 1H), 5.34 (s,
2H), 2.88 (sep, J = 6.9 Hz, 1H), 2.23 (s, 3H), 1.25 (d, J = 6.9
Hz, 6H); 13C NMR (75 MHz, CDCl3) (δ, ppm): 156.13,
148.20, 147.30, 146.71, 141.15, 130.76, 125.55, 124.22, 120.55,
120.36, 119.09, 110.06, 62.18, 34.09, 24.10, 15.90; ESI-MS
(m/z): 353.3 [M + H]+.
4.4.5. 4-(4-((5-Isopropyl-2-methylphenoxy)methyl)-1H-
1,2,3-triazol-1-yl)benzoic Acid (5e). Creamish solid, yield:
86%, mp 193−196 °C, Rf = 0.06 (ethyl acetate/hexane =
30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 8.30 (d, J =
8.4 Hz, 2H), 8.13 (s, 1H), 7.92 (d, J = 8.4 Hz, 2H), 7.09 (d, J
= 7.5 Hz, 1H), 6.88 (s, 1H), 6.80 (d, J = 7.5 Hz, 1H), 5.35 (s,
2H), 2.93−2.84 (m, 1H), 2.24 (s, 3H), 1.25 (d, J = 7.2 Hz,
6H); 13C NMR (75 MHz, CDCl3) (δ, ppm): 166.90, 156.49,
153.99, 151.43, 147.97, 145.26, 139.94, 131.57, 130.72, 123.77,
123.13, 120.32, 118.79, 110.84, 61.73, 33.89, 24.41, 16.16; ESI-
MS (m/z): 352.1 [M + H]+.
4.4.6. 4-((5-Isopropyl-2-methylphenoxy)methyl)-1-(4-
methylphenyl)-1H-1,2,3-triazole (5f). Off-white solid, yield:
88%, mp 90−92 °C, Rf = 0.71 (ethyl acetate/hexane = 30:70);
1H NMR (300 MHz, CDCl3) (δ, ppm): 7.98 (s, 1H), 7.61 (d,
J = 8.4 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 7.08 (d, J = 7.5 Hz,
1H), 6.88 (s, 1H), 6.78 (d, J = 7.5 Hz, 1H), 5.31 (s, 2H), 2.88
(sep, J = 6.9 Hz, 1H), 2.42 (s, 3H), 2.22 (s, 3H), 1.24 (d, J =
6.9 Hz, 6H); 13C NMR (75 MHz, CDCl3) (δ, ppm): 156.36,
148.10, 145.50, 138.95, 134.80, 130.64, 130.25, 124.28, 120.60,
120.54, 118.83, 110.17, 62.43, 34.10, 24.12, 21.10, 15.92; ESI-
MS (m/z): 322.3 [M + H]+.
4.4.7. 4-((5-Isopropyl-2-methylphenoxy)methyl)-1-(4-me-
thoxyphenyl)-1H-1,2,3-triazole (5g). Off-white solid, yield:
90%, mp 83−85 °C, Rf = 0.48 (ethyl acetate/hexane = 30:70);
1H NMR (300 MHz, CDCl3) (δ, ppm): 7.94 (s, 1H), 7.63 (d,
J = 8.7 Hz, 2H), 7.09−7.00 (m, 3H), 6.88 (s, 1H), 6.78 (d, J =
7.5 Hz, 1H), 5.31 (s, 2H), 3.86 (s, 3H), 2.88 (sep, J = 6.9 Hz,
1H), 2.22 (s, 3H), 1.24 (d, J = 6.9 Hz, 6H); 13C NMR (75
MHz, CDCl3) (δ, ppm): 159.89, 156.36, 148.10, 145.43,
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130.63, 130.53, 124.27, 122.28, 120.78, 118.82, 114.79, 110.16,
62.43, 55.64, 34.10, 24.12, 15.93; ESI-MS (m/z): 338.2 [M +
H]+.
4.4.8. 4-(4-((5-Isopropyl-2-methylphenoxy)methyl)-1H-
1,2,3-triazol-1-yl)benzenesulfonamide (5h). Creamish solid,
yield: 89%, mp 191−193 °C, Rf = 0.38 (ethyl acetate/hexane =
30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 8.32 (s, 1H),
8.11 (d, J = 8.7 Hz, 2H), 7.94 (d, J = 8.7 Hz, 2H), 7.07 (d, J =
7.5 Hz, 1H), 6.97−6.89 (m, 3H), 6.78 (d, J = 7.8 Hz, 1H),
5.30 (s, 2H), 2.94−2.85 (m, 1H), 2.21 (s, 3H), 1.25 (d, J = 6.9
Hz, 6H); 13C NMR (75 MHz, CDCl3) (δ, ppm): 155.74,
147.51, 145.31, 143.36, 138.59, 130.13, 127.51, 123.66, 120.49,
119.84, 118.40, 109.66, 61.57, 33.49, 23.60, 15.39; ESI-MS
(m/z): 387.2 [M + H]+.
4.4.9. 8-((1-Phenyl-1H-1,2,3-triazol-4-yl)methoxy)-
quinoline (5i). Light brown solid, yield: 85%, mp 185−187
°C, Rf = 0.31 (ethyl acetate/hexane = 30:70);
1H NMR (300
MHz, DMSO-d6) (δ, ppm): 8.99 (s, 1H), 8.03−7.95 (m, 4H),
7.90−7.81 (m, 3H), 7.46 (t, J = 8.6 Hz, 3H), 6.66 (s, 1H), 5.36
(s, 2H); 13C NMR (75 MHz, DMSO-d6) (δ, ppm): 154.29,
149.49, 144.25, 140.26, 137.07, 136.30, 130.39, 129.58, 129.25,
127.23, 123.70, 122.36, 120.67, 110.78, 62.29; ESI-MS (m/z):
303.1 [M + H]+.
4.4.10. 8-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)quinoline (5j). Light brown solid, yield: 81%, mp
163−165 °C, Rf = 0.23 (ethyl acetate/hexane = 30:70); 1H
NMR (300 MHz, DMSO-d6) (δ, ppm): 9.01 (s, 1H), 8.82 (br
s, 1H), 8.33 (d, J = 8.4 Hz, 1H), 8.01−7.96 (m, 2H), 7.56−
7.45 (m, 6H), 5.45 (s, 2H); 13C NMR (75 MHz, DMSO-d6)
(δ, ppm): 162.94, 154.32, 149.49, 144.29, 136.29, 133.62,
127.23, 123.93, 123.14, 123.02, 120.73, 117.38, 117.08, 110.81,
62.28; ESI-MS (m/z): 321.1 [M + H]+.
4.4.11. 8-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)quinoline (5k). Light brown solid, yield: 82%, mp
129−131 °C, Rf = 0.24 (ethyl acetate/hexane = 30:70); 1H
NMR (300 MHz, DMSO-d6) (δ, ppm): 9.05 (s, 1H), 8.84−
8.83 (m, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 8.7 Hz,
2H), 7.68 (d, J = 8.7 Hz, 2H), 7.55−7.52 (m, 3H), 7.46−7.44
(m, 1H), 5.46 (s, 2H); 13C NMR (75 MHz, DMSO-d6) (δ,
ppm): 154.27, 149.49, 144.44, 140.27, 136.29, 135.85, 133.54,
130.34, 129.59, 127.21, 123.75, 122.35, 120.74, 110.82, 62.28;
ESI-MS (m/z): 337.0 [M + H]+.
4.4.12. 8-((1-(4-Nitrophenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)quinoline (5l). Brown solid, yield: 82%, mp 123−
125 °C, Rf = 0.21 (ethyl acetate/hexane = 30:70);
1H NMR
(300 MHz, DMSO-d6) (δ, ppm): 9.06 (s, 1H), 8.84 (br s, 1H),
8.33 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.7 Hz, 2H), 7.69 (d, J =
8.7 Hz, 2H), 7.56−7.52 (m, 3H), 7.47−7.44 (m, 1H), 5.46 (s,
2H); 13C NMR (75 MHz, DMSO-d6) (δ, ppm): 155.42,
149.28, 148.75, 144.26, 140.89, 136.47, 135.42, 133.78, 130.71,
129.32, 127.28, 123.56, 122.48, 120.87, 110.56, 62.36; ESI-MS
(m/z): 337.2 [M + H]+.
4.4.13. 4-(4-((Quinolin-8-yloxy)methyl)-1H-1,2,3-triazol-1-
yl)benzoic Acid (5m). Light brown solid, yield: 83%, mp 276−
278 °C, Rf = 0.07 (ethyl acetate/hexane = 30:70);
1H NMR
(300 MHz, DMSO-d6) (δ, ppm): 9.13 (s, 1H), 8.84 (m, 1H),
8.34−8.32 (m, 1H), 8.13−8.10 (m, 4H), 7.56−7.47 (m, 4H),
5.48 (s, 2H); 13C NMR (75 MHz, DMSO-d6) (δ, ppm):
169.73, 155.58, 149.78, 148.19, 144.28, 140.67, 136.47, 135.69,
133.42, 130.47, 129.82, 127.47, 123.62, 122.56, 120.86, 110.70,
62.47; ESI-MS (m/z): 347.1 [M + H]+.
4.4.14. 8-((1-(4-Methylphenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)quinoline (5n). Yellowish-brown solid, yield: 80%,
mp 111−113 °C, Rf = 0.25 (ethyl acetate/hexane = 30:70); 1H
NMR (300 MHz, DMSO-d6) (δ, ppm): 8.95 (s, 1H), 8.84 (s,
1H), 8.31 (d, J = 8.1 Hz, 1H), 7.80 (d, J = 8.1 Hz, 2H), 7.55−
7.38 (m, 6H), 5.45 (s, 2H), 2.08 (s, 3H); 13C NMR (75 MHz,
DMSO-d6) (δ, ppm): 154.31, 149.47, 144.13, 140.27, 138.88,
136.30, 134.84, 130.71, 129.59, 127.22, 123.54, 122.34, 120.68,
120.54, 110.77, 62.32, 21.02; ESI-MS (m/z): 317.3 [M + H]+.
4.4.15. 8-((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)quinoline (5o). Light brown solid, yield: 82%, mp
146−148 °C, Rf = 0.19 (ethyl acetate/hexane = 30:70); 1H
NMR (300 MHz, DMSO-d6) (δ, ppm): 8.90 (s, 1H), 8.85−
8.83 (m, 1H), 8.32 (dd, J = 8.1, 1.5 Hz, 1H), 7.83 (d, J = 8.7
Hz, 2H), 7.55−7.52 (m, 3H), 7.47−7.44 (m, 1H), 7.14 (d, J =
9.0 Hz, 2H), 5.44 (s, 2H), 3.84 (s, 3H); 13C NMR (75 MHz,
DMSO-d6) (δ, ppm): 159.82, 154.31, 149.48, 143.99, 140.25,
136.29, 130.48, 129.58, 127.23, 123.65, 122.34, 120.66, 115.37,
110.70, 62.30, 56.03; ESI-MS (m/z): 333.1 [M + H]+.
4.4.16. 4-(4-((Quinolin-8-yloxy)methyl)-1H-1,2,3-triazol-1-
yl)benzenesulfonamide (5p). Light brown solid, yield: 78%,
mp 241−243 °C, Rf = 0.23 (ethyl acetate/hexane = 30:70); 1H
NMR (300 MHz, DMSO-d6) (δ, ppm): 9.13 (s, 1H), 8.34−
8.32 (m, 1H), 8.18−8.15 (m, 2H), 8.06−8.03 (m, 2H), 7.54−
7.48 (m, 5H), 5.49 (s, 2H); 13C NMR (75 MHz, DMSO-d6)
(δ, ppm): 159.79, 154.15, 149.32, 144.65, 144.41, 139.03,
136.26, 130.23, 128.01, 127.26, 123.89, 122.45, 120.91, 115.23,
110.81, 62.27; ESI-MS (m/z): 382.1 [M + H]+.
4.4.17. 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methoxy)-
naphthalene-1,4-dione (5q). Yellow solid, yield: 85%, mp
171−173 °C, Rf = 0.2 (ethyl acetate/hexane = 30:70); 1H
NMR (300 MHz, DMSO-d6) (δ, ppm): 9.03 (s, 1H), 8.30−
7.83 (m, 5H), 7.65−7.50 (m, 4H), 6.68 (s, 1H), 5.37 (s, 2H);
13C NMR (75 MHz, DMSO-d6) (δ, ppm): 184.96, 179.90,
159.34, 142.44, 136.96, 134.96, 134.11, 131.97, 131.31, 130.38,
129.37, 126.56, 126.02, 124.17, 120.77, 111.50, 62.72; ESI-MS
(m/z): 332.2 [M + H]+.
4.4.18. 2-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)naphthalene-1,4-dione (5r). Light brown solid,
yield: 82%, mp 242−244 °C, Rf = 0.28 (ethyl acetate/hexane
= 30:70); 1H NMR (300 MHz, DMSO-d6) (δ, ppm): 9.03 (s,
1H), 8.84 (br s, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.94 (d, J = 8.1
Hz, 2H), 7.61 (d, J = 7.6 Hz, 2H), 7.56−7.44 (m, 3H), 5.46 (s,
2H); 13C NMR (75 MHz, DMSO-d6) (δ, ppm): 184.98,
179.92, 159.34, 142.45, 134.99, 134.15, 133.49, 131.96, 131.30,
126.58, 126.04, 124.47, 123.26, 117.39, 117.08, 111.52, 62.68;
ESI-MS (m/z): 349.8 [M + H]+, 372.2 [M + Na]+.
4.4.19. 2-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)naphthalene-1,4-dione (5s). Light yellow solid,
yield: 87%, mp 231−233 °C, Rf = 0.31 (ethyl acetate/hexane
= 30:70); 1H NMR (300 MHz, DMSO-d6) (δ, ppm): 9.04 (s,
1H), 7.98−7.70 (m, 8H), 6.66 (s, 1H), 5.36 (s, 2H); 13C NMR
(75 MHz, DMSO-d6) (δ, ppm): 184.99, 179.83, 159.32,
142.60, 135.00, 134.15, 133.69, 131.96, 131.31, 130.36, 126.58,
126.04, 124.27, 122.49, 111.51, 62.63; ESI-MS (m/z): 366.0
[M + H]+, 388.1 [M + Na]+.
4.4.20. 2-((1-(4-Nitrophenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)naphthalene-1,4-dione (5t). Light yellow solid,
yield: 83%, mp 244−247 °C, Rf = 0.23 (ethyl acetate/hexane
= 30:70); 1H NMR (300 MHz, DMSO-d6) (δ, ppm): 9.21 (s,
1H), 8.46 (d, J = 9.0 Hz, 2H), 8.24 (d, J = 9.0 Hz, 2H), 8.02−
7.96 (m, 2H), 7.89−7.80 (m, 2H), 6.66 (s, 1H), 5.39 (s, 2H);
13C NMR (75 MHz, DMSO-d6) (δ, ppm): 184.95, 179.86,
159.27, 147.35, 143.08, 141.16, 134.98, 134.14, 131.94, 131.28,
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126.56, 126.01, 124.58, 121.34, 111.58, 62.54; ESI-MS (m/z):
377.1 [M + H]+.
4.4.21. 4-(4-((1,4-Dioxo-1,4-dihydronaphthalen-2-yloxy)-
methyl)-1H-1,2,3-triazol-1-yl)benzoic Acid (5u). Brown
solid, yield: 88%, mp 260−263 °C, Rf = 0.07 (ethyl acetate/
hexane = 30:70); 1H NMR (300 MHz, DMSO-d6) (δ, ppm):
9.12 (s, 1H), 8.10−7.96 (m, 6H), 7.85−7.81 (m, 2H), 6.65 (s,
1H), 5.36 (s, 2H); 13C NMR (75 MHz, DMSO-d6) (δ, ppm):
184.98, 179.89, 159.30, 142.79, 139.83, 134.98, 134.13, 131.95,
131.29, 126.57, 126.03, 124.27, 120.76, 111.51, 62.60; ESI-MS
(m/z): 376.2 [M + H]+.
4.4.22. 2-((1-(4-Methylphenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)naphthalene-1,4-dione (5v). Dark orange solid,
yield: 85%, mp 186−188 °C, Rf = 0.20 (ethyl acetate/hexane
= 30:70); 1H NMR (300 MHz, DMSO-d6) (δ, ppm): 8.95 (s,
1H), 8.01 (t, J = 7.8 Hz, 2H), 7.88−7.78 (m, 4H), 7.41 (d, J =
8.1 Hz, 2H), 6.66 (s, 1H), 5.35 (s, 2H), 2.39 (s, 3H); 13C
NMR (75 MHz, DMSO-d6) (δ, ppm): 184.98, 179.91, 159.34,
142.32, 139.04, 134.97, 134.71, 134.13, 131.95, 131.29, 130.73,
126.58, 126.03, 124.06, 120.62, 111.47, 62.73, 21.05; ESI-MS
(m/z): 346.2 [M + H]+.
4.4.23. 2-((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)-
methoxy)naphthalene-1,4-dione (5w). Light brown solid,
yield: 87%, mp 204−206 °C, Rf = 0.22 (ethyl acetate/hexane =
30:70); 1H NMR (300 MHz, DMSO-d6) (δ, ppm): 8.91 (s,
1H), 8.01−7.98 (m, 2H), 7.88−7.81 (m, 4H), 7.15 (d, J = 9.0
Hz, 2H), 6.67 (s, 1H), 5.34 (s, 2H), 3.84 (s, 3H); 13C NMR
(75 MHz, DMSO-d6) (δ, ppm): 184.97, 179.56, 159.40,
147.63, 143.30, 141.74, 134.54, 134.23, 131.74, 131.21, 126.87,
126.28, 124.75, 121.47, 111.37, 62.85, 55.47; ESI-MS (m/z):
362.2 [M + H]+.
4.4.24. 4-(4-((1,4-Dioxo-1,4-dihydronaphthalen-2-yloxy)-
methyl)-1H-1,2,3-triazol-1-yl) Benzene Sulfonamide (5x).
Light brown solid, yield: 85%, mp 204−206 °C, Rf = 0.25;
1H NMR (300 MHz, DMSO-d6) (δ, ppm): 9.14 (s, 1H), 8.17
(d, J = 8.4 Hz, 2H), 8.06−7.98 (m, 5H), 7.89−7.72 (m, 2H),
7.56 (s, 2H), 6.67 (s, 1H), 5.39 (s, 2H); 13C NMR (75 MHz,
DMSO-d6) (δ, ppm): 184.99, 179.89, 159.30, 144.53, 142.81,
138.93, 134.99, 134.15, 131.95, 131.29, 127.99, 126.58, 126.04,
124.41, 121.05, 111.53, 62.62; ESI-MS (m/z): 362.2 [M +
H]+.
4.5. General Procedure for the Synthesis of Sulfonic
Esters (7a−j). To a solution of natural precursors (1a−b) (1.0
mmol) in dichloromethane (10 mL) was added triethylamine
(2.0 mmol) followed by aryl/heteroaryl/aliphatic sulfonyl
chloride (6a−e) (1.5 mmol) under an inert atmosphere. The
resulting mixture was stirred at room temperature for 3−4 h.
After completion of the reaction, water was added and
dichloromethane phase was separated, dried over anhyd
sodium sulfate, and evaporated under vacuo. The crude
product was purified either by crystallization from ethanol or
by column chromatography eluted by using ethyl acetate/
hexane (3:7) to yield pure sulfonic esters.27
4.5.1. 5-Isopropyl-2-methylphenyl Benzenesulfonate (7a).
Colorless oil, yield: 89%, Rf = 0.33 (ethyl acetate/hexane =
30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 7.88 (d, J =
7.5 Hz, 2H), 7.68 (t, J = 7.4 Hz, 1H), 7.54 (t, J = 7.5 Hz, 2H),
7.08 (d, J = 7.5 Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 6.70 (s,
1H), 2.78 (sep, J = 6.9 Hz, 1H), 2.08 (s, 3H), 1.12 (d, J = 6.6
Hz, 6H); 13C NMR (75 MHz, CDCl3) (δ, ppm): 148.26,
148.07, 136.26, 134.08, 131.35, 129.12, 128.70, 128.51, 125.23,
120.12, 33.39, 23.72, 15.92; ESI-MS (m/z): 157.0.
4.5.2. 5-Isopropyl-2-methylphenyl 4-Nitrobenzenesulfo-
nate (7b). Crystalline solid, yield: 92%, mp 84−86 °C, Rf =
0.45 (ethyl acetate/hexane = 30:70); 1H NMR (300 MHz,
CDCl3) (δ, ppm): 8.39 (d, J = 8.7 Hz, 2H), 8.09 (t, J = 7.2 Hz,
2H), 7.12−7.04 (m, 2H), 6.78 (s, 1H), 2.81 (sep, J = 6.9 Hz,
1H), 2.08 (s, 3H), 1.15 (d, J = 6.9 Hz, 6H); 13C NMR (75
MHz, CDCl3) (δ, ppm): 150.97, 148.54, 147.96, 141.94,
131.69, 129.84, 128.30, 125.70, 124.27, 119.88, 33.43, 23.72,
15.93; ESI-MS (m/z): 157.0.
4.5.3. 5-Isopropyl-2-methylphenyl 4-Methylbenzenesulfo-
nate (7c). Colorless oil, yield: 85%, Rf = 0.48 (ethyl acetate/
hexane = 30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 7.74
(d, J = 8.4 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.07 (d, J = 7.8
Hz, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.71 (s, 1H), 2.77 (sep, J =
6.9 Hz, 1H), 2.45 (s, 3H), 2.08 (s, 3H), 1.12 (s, J = 6.9 Hz,
6H); 13C NMR (75 MHz, CDCl3) (δ, ppm): 148.30, 147.99,
145.19, 133.28, 131.27, 129.70, 128.71, 128.54, 125.11, 120.18,
33.39, 23.69, 21.67, 15.95; ESI-MS (m/z): 157.1.
4.5.4. 5-Isopropyl-2-methylphenyl Butane-1-sulfonate
(7d). Colorless oil, yield: 87%, Rf = 0.31 (ethyl acetate/hexane
= 30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 7.26−7.05
(m, 3H), 3.30 (t, J = 7.9 Hz, 2H), 2.93−2.84 (m, 1H), 2.31 (s,
3H), 2.05−1.95 (m, 2H), 1.60−1.50 (m, 2H), 1.23 (d, J = 6.9
Hz, 6H), 0.99 (t, J = 7.4 Hz, 3H); 13C NMR (75 MHz,
CDCl3) (δ, ppm): 148.46, 147.56, 131.51, 128.35, 125.04,
120.18, 51.04, 33.56, 25.51, 23.85, 21.50, 16.26, 13.47; ESI-MS
(m/z): 157.0.
4.5.5. 5-Isopropyl-2-methylphenyl Thiophene-2-sulfonate
(7e). Colorless oil, yield: 83%, Rf = 0.47 (ethyl acetate/hexane
= 30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 7.73 (dd, J
= 5.1, 1.2 Hz, 1H), 7.62 (dd, J = 3.9, 1.2 Hz, 1H), 7.14−7.09
(m, 2H), 7.02 (dd, J = 7.8, 1.2 Hz, 1H), 6.79 (s, 1H), 2.79
(sep, J = 6.9 Hz, 1H), 2.12 (s, 3H), 1.15 (d, J = 6.9 Hz, 6H);
13C NMR (75 MHz, CDCl3) (δ, ppm): 148.35, 148.18,
135.73, 135.09, 134.33, 131.37, 128.73, 127.54, 125.40, 119.92,
33.42, 23.74, 15.83; ESI-MS (m/z): 133.0.
4.5.6. Quinolin-8-yl Benzenesulfonate (7f). Light yellow
crystalline solid, yield: 78%, mp 111−113 °C, Rf = 0.19 (ethyl
acetate/hexane = 30:70); 1H NMR (300 MHz, CDCl3) (δ,
ppm): 8.78 (dd, J = 3.9, 1.5 Hz, 1H), 8.14 (dd, J = 8.1, 1.5 Hz,
1H), 7.99 (d, J = 7.5 Hz, 2H), 7.76 (dd, J = 8.1, 0.9 Hz, 1H),
7.63−7.59 (m, 2H), 7.53−7.43 (m, 3H), 7.40−7.36 (m, 1H);
13C NMR (75 MHz, CDCl3) (δ, ppm): 150.86, 145.52,
141.46, 140.95, 135.62, 130.25, 129.35, 128.44, 127.38, 126.41,
123.84, 121.84, 121.31; ESI-MS (m/z): 286.1 [M + H]+.
4.5.7. Quinolin-8-yl 4-Nitrobenzenesulfonate (7g). Cream-
ish crystalline solid, yield: 80%, mp 198−200 °C, Rf = 0.34
(ethyl acetate/hexane = 30:70); 1H NMR (300 MHz, CDCl3)
(δ, ppm): 8.69 (dd, J = 3.9, 1.5 Hz, 1H), 8.32 (d, J = 8.7 Hz,
2H), 8.23−8.17 (m, 3H), 7.83 (d, J = 8.1 Hz, 1H), 7.69 (d, J =
6.9 Hz, 1H), 7.57 (t, J = 7.8 Hz, 1H), 7.44−7.40 (m, 1H); 13C
NMR (75 MHz, CDCl3) (δ, ppm): 150.65, 144.89, 141.71,
140.81, 135.86, 130.14, 129.58, 127.62, 126.04, 123.72, 122.77,
122.07; ESI-MS (m/z): 331.1 [M + H]+.
4.5.8. Quinolin-8-yl 4-Methylbenzenesulfonate (7h). Off-
white solid, yield: 75%, mp 115−117 °C, Rf = 0.37 (ethyl
acetate/hexane = 30:70); 1H NMR (300 MHz, CDCl3) (δ,
ppm): 8.81 (dd, J = 4.2, 1.5 Hz, 1H), 8.12 (dd, J = 8.4, 1.8 Hz,
1H), 7.86 (d, J = 8.4 Hz, 2H), 7.73 (dd, J = 8.1, 1.2 Hz, 1H),
7.58 (dd, J = 7.5, 1.2 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H), 7.40−
7.36 (m, 1H), 7.24 (d, J = 8.4 Hz, 2H), 2.39 (s, 3H); 13C
NMR (75 MHz, CDCl3) (δ, ppm): 150.78, 145.56, 145.03,
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141.60, 135.71, 133.22, 129.62, 129.43, 128.77, 126.97, 125.98,
122.44, 121.84, 21.65; ESI-MS (m/z): 300.1 [M + H]+.
4.5.9. Quinolin-8-yl Butane-1-sulfonate (7i). Colorless oil,
yield: 79%, Rf = 0.47 (ethyl acetate/hexane = 30:70);
1H NMR
(300 MHz, CDCl3) (δ, ppm): 8.97 (dd, J = 4.2, 1.5 Hz, 1H),
8.21 (dd, J = 8.4, 1.5 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.73
(d, J = 7.5 Hz, 1H), 7.55 (t, J = 7.8 Hz, 1H), 7.50−7.46 (m,
1H), 3.62 (t, J = 7.8 Hz, 2H), 2.16−2.05 (m, 2H), 1.59−1.47
(m, 2H), 0.98 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz,
CDCl3) (δ, ppm): 150.79, 145.52, 141.44, 136.13, 129.73,
126.93, 126.33, 128.55, 122.00, 51.83, 25.51, 21.51, 13.47; ESI-
MS (m/z): 266.2 [M + H]+.
4.5.10. Quinolin-8-yl Thiophene-2-sulfonate (7j). Cream-
ish solid, yield: 85%, mp 103−105 °C, Rf = 0.24 (ethyl acetate/
hexane = 30:70); 1H NMR (300 MHz, CDCl3) (δ, ppm): 8.81
(dd, J = 4.2, 1.8 Hz, 1H), 8.14 (dd, J = 8.4, 1.8 Hz, 1H), 7.76
(dd, J = 8.1, 1.2 Hz, 1H), 7.68 (dd, J = 3.9, 1.5 Hz, 1H), 7.65−
7.62 (m, 2H), 7.52 (t, J = 10.2 Hz, 1H), 7.41−7.37 (m, 1H),
7.01 (t, J = 4.4 Hz, 1H); 13C NMR (75 MHz, CDCl3) (δ,
ppm): 150.87, 145.55, 141.53, 135.75, 135.50, 135.34, 134.42,
129.58, 127.29, 126.02, 122.72, 121.92; ESI-MS (m/z): 292.0
[M + H]+.
4.6. X-ray Crystallographic Analysis. The structures of
compounds 5c, 5f, 7g, and 7h were unambiguously established
by X-ray crystallographic analysis. Single crystals of 5c, 7g, and
7h were obtained through the slow evaporation of their mixed
solvent system containing dichloromethane, hexane, methanol,
and ethyl acetate, whereas single crystal of 5f was obtained
through the slow evaporation of its ethyl acetate and hexane
solution. Suitable crystal of compound 5c (C19H20ClN3O) was
selected and analyzed on a Nonius Kappa charge-coupled
device (CCD) diffractometer, and single crystals of com-
pounds 5f (C20H23N3O) and 7g (C15H10N2O5S) were
analyzed on a D8 Venture Dual Source 100 CMOS
diffractometer (Karlsruhe, Germany) equipped with Cu
radiation (Cu Kα = 1.54178 Å). For analyzing the single
crystal of compound 7h (C16H13NO3S), a Bruker APEX II
Kappa CCD diffractometer was utilized. Intensity data were
collected at 100 K using ϕ and ω scans. No significant loss in
intensities was observed during data collection. Multiscan
absorption corrections were applied to the intensity data
empirically using Denzo for 5c28 and SADABS V2014/229 for
5f, 7g, and 7h. Data collection, reduction, and refinement were
performed using COLLECT,30 Denzo-SMN,31 and SHELXL-
9732 softwares for 5c, and for 5f, 7g, and 7h, APEX2 V2014.5-
0,33 SAINT V8.34A,34 and SHELXL-201435 softwares were
used, respectively. Crystal structures were solved by direct
methods using SHELXL-9736 for 5c and SHELXT-201435 for
5f, 7g, and 7h and refined with full-matrix least-squares based
on F2 using SHELXT-2014.35 All nonhydrogen atoms were
refined anisotropically. Hydrogen atoms were first located in
the Fourier difference map, then positioned geometrically, and
allowed to ride on their respective parent atoms. The
molecular graphics and crystallographic illustrations were
prepared using XP.37,38
4.7. In Vitro Antimicrobial Activity. All synthesized
compounds (5a−x and 7a−j) were screened for their in vitro
antibacterial activity against S. pneumoniae (MTCC 655), E.
faecalis (MTCC 439), P. aeruginosa (MTCC 2453), S. enterica
(MTCC 3224), K. pneumoniae (ATCC 700603), E. coli
(ATCC 25922), and multidrug-resistant strains viz. E. coli
MRA11 (GenBank accession no. KJ957160), MRC17
(GenBank accession no. KJ906623), MRC24 (GenBank
accession no. KM822765), MRAE26 (GenBank accession
no. KJ923014), MRAE32 (GenBank accession no. KJ923017),
MRAE33 (GenBank accession no. KM822768), MRAE44
(GenBank accession no. KJ923018), and MROB11 (GenBank
accession no. KC963018) using the broth dilution technique
according to the standard protocol for antibacterial assessment
by CLSI.39 CIP was used as a positive control for the studies.
All compounds were dissolved in DMSO and serially diluted in
broth medium to achieve the final concentration of DMSO less
than 4%. Varying concentrations (1000 to 7.8 μg/mL) of test
compounds were dispensed into a 96-well plate in nutrient
broth in a final volume of 100 μL. Then, 100 μL of bacterial
cells (approximately 2.5 × 106 cells/mL) was dispensed into
the 96-well plate (Tarson) and incubated at 37 °C for
overnight. After the incubation period, each well was analyzed
for the presence or absence of visual growth of bacterial cells.
The lowest concentration of the test compound at which no
visible growth occurs represents its MIC value. Moreover, after
incubation, the growth was measured turbidometrically at 600
nm using a Thermo Multiskan Go spectrophotometer. IC50
was determined as 50% inhibition of bacterial cell growth and
calculated by plotting a graph between concentration (log10)
and % inhibition. In the case of MDR isolates, varying
concentrations (8−1024 μg/mL for 5e and 5u and 0.49−63.3
μg/mL for CIP) were dispensed into a 96-well plate (Tarson)
in Luria broth medium. Then, the medium was inoculated with
10 μL of 1000 times diluted 0.1OD600 culture and incubated
overnight at 37 °C. The optical density (OD) was measured at
600 nm using a microplate reader (Thermo Scientific
Multiskan Go). Percentage inhibition of these resistant isolates
was calculated using the formula
= − ×a b aPercentage inhibition / 100
where a = pure culture reading − media reading and b = test
reading − plain compound reading (if the compound is a
colored solution).
4.8. Synergistic Study. The antimicrobial activity of the
test compounds in combination with CIP was determined
following the checkerboard method. A 96-well microtiter plate
was inoculated with 100 μL of Mueller-Hinton broth followed
by addition of compounds 5e and 5u with the concentration
ranging from 1024 to 16 μg/mL and CIP with the
concentration ranging from 128 to 2 μg/mL. Each well was
inoculated with 100 μL of a suspension of 5 × 105 CFU/mL in
a final volume of 200 μL. Inocula were prepared by direct
suspension in Mueller-Hinton broth of bacteria grown
overnight on MacConkey medium in order to obtain 0.5
McFarland standard. The checkerboard plates were then
incubated for overnight at 37 °C. The FICI is defined as the
sum of the MICs of each drug when used in combination
divided by the MIC of the drug used alone. Synergy and
antagonism were defined by FICI ≤ 0.5 and >4, respectively.
Partially synergistic was denoted by 0.5 > FICI < 1, whereas
indifferent was defined by 1 < FICI ≤ 4.40
4.9. Growth Kinetic Studies. The bacterial strains S.
pneumoniae and E. coli were freshly revived by subculturing on
the nutrient agar plate. A loop of inoculum was introduced into
the nutrient broth medium and incubated in an automated
incubator shaker for 12 h at 37 °C. On the second day, approx.
2 × 106 cells/mL of overnight grown culture were inoculated
in 50 mL of sterile nutrient broth medium. Different
concentrations (2MIC, MIC, and MIC/2) of inhibitors 5e
and 5u were added into the culture medium and incubated at
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37 °C and 160 rpm. CIP at a concentration 10 μg/mL was
used as a positive control drug. Aliquots (1 mL) of culture
were removed from each test sample at time interval of 2 h
(i.e., time points of 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22
h), and growth was measured turbidometrically at 600 nm
using a Thermo Multiskan Go spectrophotometer. OD was
recorded for each concentration against time (h).41
4.10. TEM Analysis. The morphology of S. pneumoniae and
E. coli cells was analyzed using TEM following the standard
protocol.42 Briefly, the cells were harvested, standardized (A600
≈ 0.1), and exposed to 62.5 and 125 μg/mL concn of test
inhibitors 5e for E. coli and S. pneumoniae, respectively, and
125 μg/mL of 5u for both the strains for 1 h. Then, the cells
were washed thrice with phosphate-buffered saline (PBS) to
remove the residual medium and fixed overnight in 2.5%
glutaraldehyde in phosphate/magnesium buffer (40 mM
K2HPO4/KH2PO4, pH 6.5, 0.5 mM MgCl2). The cells were
washed twice for 15 min in 0.1 M sodium phosphate buffer
(pH 6.0) and postfixed for 2 h in 2% osmium tetroxide. Again,
the cells were washed twice for 15 min in distilled water and
then en bloc stained with 1% uranyl acetate (aqueous) for 30
min. After two further washes, cells were dehydrated in 95 and
100% ethanol. The cells were exposed to propylene oxide for 2
× 10 min and infiltrated for 1 h in 1:1 propylene/epoxy
embedding material (Epon) mixture and then overnight in
fresh Epon. After polymerization for 48 h at 60 °C, ultrathin
sections were cut using a microtome (Leica EM UC6) and
transferred onto a copper grid. The samples were stained with
uranyl acetate (saturated solution of uranyl acetate in 50%
alcohol) followed by lead citrate. The samples were washed
three times in Milli-Q water and dried by blotting with
Whatman filter paper. The sections were examined with a
Tecnai G2 20 high-resolution transmission electron micro-
scope (Fei Company, The Netherlands) at 200 kV.
4.11. Assessment of Anti-Biofilm Activity by XTT
Assay. A semi-quantitative measurement of metabolic activity
of bacterial biofilm was obtained from the XTT (2,3-bis(2-
methoxy-4-nitro-5-sulphophenyl)-5-[(phenylamino)carbonyl]-
2H-tetrazolium-hydroxide) reduction assay.43 A serial 2-fold
dilution pattern was prepared in the medium wells with the
concentration of antibacterial agents ranging from 7.812 to
1000 μg/mL. Aliquots of 100 μL of tryptic soy broth (TSB)
with a bacterial inoculum of 5 × 105 CFU/mL were added to
each well and incubated at 37 °C for 24 h under static
conditions. The medium was discarded and washed with PBS
to remove the nonadherent bacteria. To each well, 50 μL of
prepared XTT salt solution (HiMedia, India) was added and
plates were incubated at 37 °C in dark for 90 min. Bacterial
dehydrogenase activity reduces XTT tetrazolium salt to XTT
formazan, resulting in colorimetric change (turns to orange)
that was correlated with cell viability. The colorimetric changes
were measured spectrophotometrically at 490 nm.44 The %
inhibition data were interpreted from dose−response curves.
4.12. Assessment of Anti-Biofilm Activity by Crystal-
Violet Assay. Biofilm formation by E. coli and S. pneumoniae
was investigated using crystal violet assay based on the
methods of O’Toole & Kolter.45 Cultures were grown in TSB
(containing 2.5 g/L glucose) until OD600 reached 0.1
(equivalent to 0.5 McFarland). The cultures were diluted in
fresh TSB medium in a 1:1 ratio (added 100 μL of culture in
100 μL of broth), and polystyrene 96-well microtitre plates
were filled with 200 μL of culture per well and incubated at 37
°C for 48 h. After incubation, cultures were removed and
microtitre plate wells were gently washed four times with 200
μL of sterile PBS (1× PBS, pH7.2) to remove loosely
associated bacteria. Cells that had adhered to the wells were
stained with 200 μL of 0.1% (w/v) crystal violet at room
temperature for 20 min. The wells were washed again with 1×
PBS or sterile distilled water. The crystal violet that had stained
the cells was solubilized in 250 μL of 95% (v/v) ethanol. The
samples were incubated for 20 min at room temperature, and
biofilm formation was quantified by measuring the OD at 590
nm in an ELISA plate reader (Thermo Scientific, Multiscan
Go). To observe the change in the amount of biofilm
formation in the presence of compounds 5e, 5u, and CIP at a
subinhibitory level, TSB medium was supplemented with 125,
250, and 8 μg/mL, respectively, for E. coli and 250, 250, and 8
μg/mL, respectively, for S. pneumoniae. The wells containing
TSB medium alone were used as blank.
The percentage of biofilm inhibition was calculated by the
formula
= − ×a b aPercentage inhibition / 100
where a = pure culture reading − media reading and b = test
reading − plain compound reading (if the compound is a
colored solution).
4.13. Assessment of Biofilm Inhibition by SEM
Analysis. SEM analysis was performed to determine the
biofilm formation by E. coli. The fresh bacterial cultures were
prepared and inoculated into six-well cell culture plates
containing 3 mL of TSB (containing 2.5 g/L glucose). Glass
coverslips (8 mm diam) were dispensed into each well for
biofilm formation on the surface and incubated at 37 °C for 24
h. Post incubation, plates were removed and test compounds
were added to determine the anti-biofilm effect. Parafilm-
sealed plates were further incubated for the next 24 h.
Coverslips were removed after total incubation of 24 h and
washed with 0.1 M PBS. Biofilms that formed on the coverslips
were placed in a fixative (4%, v/v, formaldehyde in PBS)
overnight. Samples were again washed with PBS, and then
coverslips were left to dry and later examined under a scanning
electron microscope.46
4.14. Cytotoxicity by MTT Assay. MTT (3-(4,5-
Dimethyl-2-yl)-2,5-diphenyl tetrazolium bromide), Dulbecco’s
modified Eagle’s medium (DMEM), 0.25% trypsin, and a
0.02% ethylenediaminetetraacetic acid (EDTA) mixture were
purchased from HiMedia (Mumbai, India). Fetal bovine serum
(FBS) was obtained from Gibco (Grand Island, NY). The
human embryonic kidney (HEK293) cell line was procured
from National Centre for Cell Sciences (NCCS), Pune, India.
The cells were cultured and maintained as a monolayer in
DMEM supplemented with 10% FBS and antibiotics (100
units/mL penicillin and 100 μg/mL streptomycin) at 37 °C in
a humidified atmosphere of 5% CO2 in T-25 flasks. The cells
were subcultured twice in a week. A cell count of
approximately 2 × 104 cells per well was seeded in a 96-well
plate (150 μL per well) and incubated for 24 h before
treatment. The cells were then treated with varying
concentrations (10−400 μg/mL) of the test compounds.
After 48 h of incubation at 37 °C, the exhausted serum-
supplemented medium was removed and serum-free medium
(50 μL) was added into each well. After that, 20 μL per well of
MTT at a concentration of 5 mg/mL in PBS was added to
each well and the plates were incubated for 4 h at 37 °C.
Formazan crystals, the metabolized MTT product, were
solubilized in DMSO (150 μL per well) and were quantified
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by reading the absorbance at 570 nm after incubation of 10
min on an iMark microplate reader (Bio-Rad, Hercules, CA).
All assays were performed in triplicate. Percent viability was
taken as the relative absorbance of treated versus untreated
control cells.21
4.15. Hemolytic Assay. The hemolytic activities of the
test inhibitors 5e and 5u and the conventional antibacterial
drug CIP (HiMedia) were determined on hRBCs.21 Human
erythrocytes from healthy individuals were collected in tubes
containing EDTA as an anticoagulant. The erythrocytes were
harvested by centrifugation for 10 min at 2000 rpm and 20 °C
and washed three times in PBS. To the pellet, PBS was added
to yield a 10% (v/v) erythrocyte/PBS suspension. The 10%
suspension of erythrocytes was then further diluted with PBS
at a 1:10 ratio. The final diluted erythrocytes (100 μL) were
added to 100 μL of PBS having a previously determined
concentration gradient (1000 to 7.8 μg/mL) of test
compounds in microcentrifuge tubes. Total hemolysis was
achieved with 1% Triton X-100. The tubes were incubated for
1 h at 37 °C and then centrifuged for 10 min at 2000 rpm and
at room temperature. From the supernatant fluid, 150 μL was
transferred to a flat-bottomed microtitre plate (Tarson), and
the absorbance was measured spectrophotometrically at 450
nm by using a Thermo Multiskan Go spectrophotometer. The
hemolysis percentage was calculated by following the equation:
= [
−
‐
− ] ×
A
A
A
A
% Hemolysis ( of test compound treated sample
of buffer treated sample)
/( of 1% Triton X 100 treated sample
of buffer treated sample) 100%
450
450
450
450
where A450 is absorbance at 450 nm.
4.16. In Vivo Toxicity Evaluation of 5e and 5u in G.
mellonella Larvae. The larvae of the sixth developmental
stage of G. mellonella were obtained from the Mealworm
Company (Sheffield, England). The larvae of G. mellonella
were stored in wood shavings in the dark at 15 °C prior to use.
The larvae that were chosen for experiments weighed 0.21 g
and were used within 3−4 weeks of receipt. Ten healthy larvae
were placed in sterile 9 cm Petri dishes with Whatman filter
paper inserted inside. A culture of S. pneumoniae and E. coli was
grown to the stationary phase (1−2 × 108/mL) in YEPD broth
at 30 °C and 200 rpm. The cells were harvested by
centrifugation (2056g for 5 min on a Beckmann GS-6 bench
centrifuge), washed in PBS, and resuspended in PBS at a cell
density 5 × 105 per 20 μL. The larvae were inoculated by
injecting 20 μL through the last left proleg into the hemocoel
using a Myjector syringe (Terumo Europe) and placed at 30
°C in the dark. One hour post inoculation, the larvae were
inoculated with compounds 5e and 5u, both at a
concentrations of 2.5 mg suspended in PBS, and supplemented
with 12.5% DMSO (v/v), through the last right proleg. The
larvae injected with 20 μL of PBS supplemented with 12.5%
DMSO (v/v) were used as controls. For assessment of larval
viability, the larvae were gently probed with a needle, and if no
response was observed, the larvae were considered to be dead.
Three larvae were inoculated with 20 μL of 5e and 5u
solutions at a concentration of 1.25 or 2.5 mg/mL. The larvae
were then incubated at 30 °C, in the dark, for 24 h. The
hemocyte density in the larvae was ascertained by piercing the
backs of the anterior end (“head”) of the three larvae with a
sterile needle and collecting the yellow hemolymph (“blood”),
ensuring no white floccular material was removedthis is the
fat body and will impede counting. Hemolymph was diluted to
1 in 10 in cold PBS containing 0.37% (v/v) 2-mercaptoethanol
to reduce clotting and melanization. The solution was mixed
gently by pipetting. Hemocytes were counted on a
hemocytometer (0.0025 mm2, BLAUBRAND, Germany),
and the density in the original larvae was calculated.21
4.17. ADME Profiling. A computational study to predict
ADME properties of the synthesized compounds (5a−x and
7a−j) was performed using QikProp version 3.2, Schrödinger
software. Various physicochemical significant descriptors as
well as pharmacokinetically relevant properties such as
molecular weight, number of hydrogen bond acceptors/
donors, NRBs, aqueous solubility, brain/blood partition
coefficient, binding to human serum albumin, and % human
oral absorption of the compounds were evaluated. In
particular, Lipinski’s rule of 5 was compiled for all synthesized
compounds, which is widely used as a filter to identify easily
bioavailable drugs. Moreover, QikProp provides ranges to
compare molecule properties with those of 95% of known
drugs.24
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